Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31282074 | 0.86 | LMNA (0.44) | LMNAPOLBSMN1; SMN2GPR119 | |
| SCHEMBL30135739 | 0.85 | LMNA (0.50) | LMNAPOLBSMN1; SMN2GPR119OPRD1 | |
| SCHEMBL30225407 | 0.83 | SMN1; SMN2 (0.54) | LMNAPOLBSMN1; SMN2GPR119OPRD1 | |
| SCHEMBL21384398 | 0.82 | SMN1; SMN2 (0.52) | LMNAPOLBSMN1; SMN2GPR119OPRD1 | |
| SCHEMBL30177238 | 0.82 | SMN1; SMN2 (0.52) | LMNAPOLBSMN1; SMN2GPR119OPRD1 | |
| SCHEMBL7448604 | 0.82 | LMNA (0.55) | LMNAPOLBSMN1; SMN2GPR119 | |
| SCHEMBL30001960 | 0.82 | SMN1; SMN2 (0.49) | LMNAPOLBSMN1; SMN2GPR119OPRD1 | |
| SCHEMBL30002152 | 0.80 | SMN1; SMN2 (0.50) | LMNAPOLBSMN1; SMN2GPR119OPRD1 | |
| SCHEMBL29655416 | 0.79 | LMNA (0.50) | LMNAPOLBSMN1; SMN2 | |
| SCHEMBL30177282 | 0.77 | LMNA (0.50) | LMNAPOLBSMN1; SMN2GPR119OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | LMNA 2896/4885POLB 3069/4885SMN1; SMN2 1781/4885 |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | LMNA 2219/4885POLB 845/4885SMN1; SMN2 3149/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | LMNA 3419/4885POLB 2202/4885SMN1; SMN2 2413/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | LMNA 3086/4885POLB 1044/4885SMN1; SMN2 737/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | LMNA 3765/4885POLB 2001/4885SMN1; SMN2 960/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | LMNA 1420/4885POLB 3633/4885SMN1; SMN2 3358/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885POLB 2088/4885SMN1; SMN2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.